Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067457 · ClinicalTrials.gov registry record · Phase 3
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
NCT00067457 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 700 participants.
The verdict
NCT00067457, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
Interventions
- DRUG alosetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067457
The ClinicalTrials.gov registry entry for NCT00067457 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alosetron is the first listed.
NCT00067457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067457 about?
NCT00067457 is a clinical study titled "Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy". The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
What is the current status of trial NCT00067457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2003-06. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00067457?
The interventions under investigation include: alosetron (DRUG).
Who is sponsoring clinical trial NCT00067457?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.